$BTTX News
Last published 2y ago
- 2y agoBTTXBetter Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from NasdaqBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX) (the "Company") announced today that the Company is terminating its employees and will explore strategic alternatives, including assignment for the benefit of creditors and/or a
- 2y agoBTTXBetter Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health CentersBusiness WireOne million prescriptions for AspyreRx will be offered to patients in underserved communities disproportionately affected by type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing
- 2y agoBTTXBetter Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)Business WireCompany to host sponsored education session on Saturday, March 09, 2024; Expanding access to a high quality and effective lifestyle modification intervention Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in
- 2y agoBTCYBTTXBetter Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVACCESS NewswireORLANDO, FL / ACCESSWIRE / March 1, 2024 / RedChip Companies will air interviews with Better Therapeutics, Inc. and Biotricity, Inc. on the RedChip Small Stocks, Big Money™ show, a
- 2y agoBTTXBetter Therapeutics Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver DiseaseBusiness WireSignifies the FDA's recognition of the Company's novel Cognitive Behavioral Therapy as a potential treatment for metabolic dysfunction-associated steatohepatitis Opens an accelerated path towards a potential second
- 2y agoBTTXBetter Therapeutics Signs Rebate Agreement with One of the Largest Pharmacy Benefit Managers in the US for its AspyreRx Diabetes TreatmentBusiness WireAgreement is an important step towards securing broad coverage Better Therapeutics Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today
- 2y agoBTTXBetter Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care AloneBusiness WireOver a lifetime horizon AspyreRx plus standard of care (SoC) was estimated to be superior to SoC alone providing more life years and improvements in quality of life at a lower cost Study suggests that using AspyreRx
- 2y agoBTTXBetter Therapeutics Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver DiseaseBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics (PDTs) to treat cardiometabolic diseases, today announced it has submitted a request to the U.S. Food and Drug
- 2y agoBTTXBetter Therapeutics Strengthens Financial Position Through Amendment to Debt Facility and Implementation of Cost ReductionsBusiness WireSavings Expected to Extend Cash Runway Sufficiently to Demonstrate Commercial Traction with AspyreRx in Type 2 Diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital
- 2y agoBTTXFrost & Sullivan Honors Better Therapeutics with the 2023 Technology Innovation Leadership AwardBusiness WireBetter Therapeutics is recognized for its novel cognitive behavioral therapy app, AspyreRx™, leading the way in the North American diabetes digital behavioral therapeutics industry Better Therapeutics, Inc.
- 3y agoBTTXBetter Therapeutics, Inc. (BTTX) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoBTTXBetter Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdatesBusiness WireCompany obtained FDA authorization for AspyreRxTM to treat adults with type 2 diabetes and announced commercial launch Company to host a conference call and webcast today at 8:30 a.m. ET Better Therapeutics, Inc.
- 3y agoBTTXBetter Therapeutics to Release Third Quarter 2023 Financial Results and Provide Business Update on November 09, 2023Business WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its third quarter 2023 financial results before the
- 3y agoBTTXBetter Therapeutics to Participate in the American College of Lifestyle Medicine's 2023 Annual ConferenceBusiness WireCompany to showcase AspyreRx™ Company to host sponsored education session on Tuesday, October 31, 2023; A novel approach to treating type 2 diabetes Better Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in
- 3y agoBTTXBetter Therapeutics Announces Launch of AspyreRxTM to Treat Adults with Type 2 DiabetesBusiness WireAspyreRx is the first FDA-authorized digital behavioral therapeutic device delivering cognitive behavioral therapy for the treatment of a cardiometabolic disease As previously reported, adding AspyreRx to standard of
- 3y agoBTTXBetter Therapeutics Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 DiabetesBusiness WirePivotal trial established use of AspyreRx alongside standard of care demonstrating clinically meaningful and statistically significant reduction in HbA1c leading to FDA authorization In a subgroup analysis, the use of
- 3y agoBTTXBetter Therapeutics Announces Publication of LivVita Liver Disease Study Results in Gastro Hep AdvancesBusiness WireAuthors conclude the totality of positive efficacy, safety and usability data indicates the potential of Better Therapeutics' digitally delivered Cognitive Behavioral Therapy to help address the significant unmet
- 3y agoBTTXBetter Therapeutics Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 DiabetesBusiness Wire1,000 participants enrolled across two studies, and six sites Studies will evaluate clinical effectiveness beyond 6 months, impact on medication use and healthcare utilization Better Therapeutics, Inc.
- 3y agoBTTXBetter Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdatesBusiness WireObtained FDA Authorization for AspyreRxTM to treat adults with type 2 diabetes Established price and launch metrics in preparation for expected launch in Q4 Completed financing transactions totaling $12.5 million in
- 3y agoBTTXBetter Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023Business WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the
- 3y agoBTTXBetter Therapeutics Announces $6.7 Million in New Financing at an Average Price of $0.77 per ShareBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a pioneer in developing software to treat cardiometabolic diseases, today announced that it issued 2,023,583 shares of its common stock under its At-The-Market program at an
- 3y agoBTTXBetter Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 DiabetesBusiness WireFirst prescription digital behavioral therapeutic device delivering novel form of cognitive behavioral therapy via smartphone In a randomized controlled trial AspyreRx demonstrated clinically meaningful and
- 3y agoBTTXBetter Therapeutics Announces Upcoming Poster Presentation at EASL Congress 2023 in Vienna, AustriaBusiness WireNaim Alkhouri, MD, FAASLD, to Present Findings from Non-alcohol Related Fatty Liver Disease Feasibility Study Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a
- 3y agoBTTXBetter Therapeutics Reports First Quarter 2023 Financial Results and Provides Business UpdatesBusiness WireOn track for an FDA decision mid-year Announced restructuring to extend cash runway Completed private placement financing Company to host conference call and webcast today at 8:30 a.m. ET Better Therapeutics,
- 3y agoBTTXBetter Therapeutics to Release First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023Business WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of
- 3y agoBTTXBetter Therapeutics Announces $6.5MM Private PlacementBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based, novel form of cognitive behavioral therapy (CBT) to address the root causes
- 3y agoBTTXBetter Therapeutics, Inc. (BTTX) Q4 2022 Financial Results Conference Call TranscriptEarnings Call Transcripts
- 3y agoBTTXBetter Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesBusiness WireAdvanced preparations for potential commercial launch of BT-001 in U.S. in mid-2023 Reported positive topline results from exploratory trial for fatty liver disease Announced restructuring and other cost saving
- 3y agoBTTXBetter Therapeutics to Release Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 30, 2023Business WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of
- 3y agoBTTXBetter Therapeutics to Participate in Two Upcoming Investor ConferencesBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a clinically validated, software-based novel form of cognitive behavioral therapy to address the root causes of
- 3y agoBTTXBetter Therapeutics Completes Exploratory Trial for Fatty Liver Disease and Announces Positive Topline ResultsBusiness WireStudy Conducted with Arizona Liver Health Met Primary Endpoint and Established Proof-of-Concept for Prescription Digital Therapy Platform to Improve Disease Biomarkers in NAFLD and NASH Patients Company Intends to
- 3y agoBTTXBetter Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that
- 3y agoBTTXBetter Therapeutics to Participate in BTIG Digital Health ForumBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics company developing a novel form of cognitive behavioral therapy to address the root causes of cardiometabolic diseases, today announced that
- 3y agoBTTXBetter Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesBusiness WireU.S. FDA accepted the company's submission of its de novo request for BT-001 investigational prescription digital therapy for type 2 diabetes in adults BT-001 pivotal clinical trial 90-day results published in
- 4y agoBTTXBetter Therapeutics to Release Third Quarter 2022 Financial Results and Provide Business Update on November 14, 2022Business WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, today
- 4y agoBTTXBetter Therapeutics Appoints Diane Gomez-Thinnes as Chief Commercial OfficerBusiness WireIndustry Veteran Joins Health Technology Pioneer to Bring Prescription Digital Therapeutics for Type 2 Diabetes and other Cardiometabolic Conditions to Market Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription
- 4y agoBTTXPositive Results from Pivotal Trial of Better Therapeutics' Investigational BT-001 Prescription Digital Therapy for Type 2 Diabetes Published in Diabetes CareBusiness WireADA-published, peer-reviewed journal article highlights positive primary endpoint data from trial evaluating digitally delivered approach to diabetes management Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) compan
- 4y agoBTTXBetter Therapeutics Submits De Novo Request to U.S. FDA for BT-001 Investigational Prescription Digital Therapy for Type 2 DiabetesBusiness WireSubmission follows completion of first-in-class trial demonstrating significant improvements in A1c reduction with investigational therapy targeting the root causes of type 2 diabetes. Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital t
- 4y agoBTTXBetter Therapeutics to Participate in Three Upcoming Investor ConferencesBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe, Chief Executi
- 4y agoBTTXBetter Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateBusiness WireCompleted pivotal trial of BT-001 for type 2 diabetes and reported positive secondary endpoint results after 180 days of treatment On track to submit de novo classification request for BT-001 with FDA in third quarter of 2022 Completed enrollment
- 4y agoBTTXBetter Therapeutics to Release Second Quarter 2022 Financial Results and Provide Business Update on August 11, 2022Business WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will release its second quar
- 4y agoBTTXBetter Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint ResultsBusiness WireData demonstrates BT-001 was durable with A1c reductions continuing to improve after 180 days of treatment On track to submit a de novo classification request with FDA for BT-001 in third quarter of 2022 Company to host conference call and webcast
- 4y agoBTTXBetter Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 DiabetesBusiness WireConference call and webcast on Thursday, July 28, 2022, at 8:30 a.m. ET Better Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes o
- 4y agoBTTXBetter Therapeutics Announces Publication of the Rationale, Design and Baseline Characteristics Manuscript for Type 2 Diabetes Pivotal Trial of BT-001, a Novel Prescription Digital Therapy, in Clinical CardiologyBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the publication of a manuscript detai
- 4y agoBTTXBetter Therapeutics to Participate in Cowen 7th Annual FutureHealth ConferenceBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Kevin Appelbaum, Co-Founde
- 4y agoBTTXBetter Therapeutics to Participate in Cowen's Unlocking the Value of Digital Prescription Therapeutics Webinar on June 16, 2022Business WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that it will participate in a w
- 4y agoBTTXBetter Therapeutics Announces Issuance of U.S. Patent Covering Key Features of Their Prescription Digital Therapeutics PlatformBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that the U.S. Patent and Trade
- 4y agoBTTXEXELMYOVBetter Therapeutics Appoints Frank Karbe as Chief Executive OfficerBusiness WireBetter Therapeutics, Inc. (NASDAQ:BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced that Frank Karbe will join the
- 4y agoBTTXBetter Therapeutics to Host Virtual Educational Webinar Symposium on New American Diabetes Association Guidelines Recommending Digital Tools in Diabetes CareBusiness WireLeading Medical Experts to Discuss Promising Developments on Prescription Digital Therapeutics and Nutritional Cognitive Behavioral Therapy for Type 2 Diabetes Patients Better Therapeutics, Inc. (("Better Therapeutics", NASDAQ:BTTX), a prescription d
- 4y agoBTTXBetter Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate MilestonesBusiness WireReported positive primary endpoint results from pivotal trial of BT-001 after 90 days of treatment for type 2 diabetes Represents a first-in-class randomized, controlled clinical trial of a prescription digital therapeutic (PDT) for treating a cardio